Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Vaccines
ImQuest Publishes Results of Important Structure Activity Relationship Program on Dual Acting Pyrimidinediones
April 15th, 2008
ImQuest BioSciences, Inc. announced the publication of the results of an important structure- activity relationship study to investigate the efficacy and toxicity of a series of pyrimidinedione analogs against HIV-1 and HIV-2. The manuscript, published in the journal Antiviral Chemistry and Chemotherapy, shows the results of ImQuest's HIV drug development program based on compounds which it licensed from Samjin Pharmaceutical Co. Ltd. The report, authored by Robert W. Buckheit, Jr., Ph.D. (Executive Vice President and Chief Scientific Officer of ImQuest) describes the synthesis of the highly potent pyrimidinedione series and the structural features of the compounds which are responsible...
Source: Cancer Weekly (2008-04-15)
|
